CN111303146A - 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途 - Google Patents

3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途 Download PDF

Info

Publication number
CN111303146A
CN111303146A CN201811509630.6A CN201811509630A CN111303146A CN 111303146 A CN111303146 A CN 111303146A CN 201811509630 A CN201811509630 A CN 201811509630A CN 111303146 A CN111303146 A CN 111303146A
Authority
CN
China
Prior art keywords
compound
reacting
generate
solvent
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811509630.6A
Other languages
English (en)
Chinese (zh)
Inventor
杨玉社
孔德瑜
薛涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN201811509630.6A priority Critical patent/CN111303146A/zh
Priority to PCT/CN2019/123507 priority patent/WO2020119590A1/fr
Publication of CN111303146A publication Critical patent/CN111303146A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201811509630.6A 2018-12-11 2018-12-11 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途 Pending CN111303146A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201811509630.6A CN111303146A (zh) 2018-12-11 2018-12-11 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途
PCT/CN2019/123507 WO2020119590A1 (fr) 2018-12-11 2019-12-06 Composé de 3-cyanopyridine, composition pharmaceutique le contenant, son procédé de préparation et ses applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811509630.6A CN111303146A (zh) 2018-12-11 2018-12-11 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN111303146A true CN111303146A (zh) 2020-06-19

Family

ID=71077124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811509630.6A Pending CN111303146A (zh) 2018-12-11 2018-12-11 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN111303146A (fr)
WO (1) WO2020119590A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736094A (zh) * 2023-12-18 2024-03-22 江苏百奥信康医药科技有限公司 一种左卡尼汀有关物质的合成制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137643A (zh) * 2005-01-06 2008-03-05 阿斯利康(瑞典)有限公司 新型吡啶化合物
WO2008085119A1 (fr) * 2007-01-12 2008-07-17 Astrazeneca Ab Nouveaux analogues de la pyridine viii 518
CN101263133A (zh) * 2005-07-13 2008-09-10 阿斯利康(瑞典)有限公司 新的吡啶类似物
WO2010005385A1 (fr) * 2008-07-07 2010-01-14 Astrazeneca Ab Dérivés de pyridine substitués par 2-amino-6-alkyle utiles comme inhibiteurs de p2y12

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137643A (zh) * 2005-01-06 2008-03-05 阿斯利康(瑞典)有限公司 新型吡啶化合物
CN101263133A (zh) * 2005-07-13 2008-09-10 阿斯利康(瑞典)有限公司 新的吡啶类似物
WO2008085119A1 (fr) * 2007-01-12 2008-07-17 Astrazeneca Ab Nouveaux analogues de la pyridine viii 518
WO2010005385A1 (fr) * 2008-07-07 2010-01-14 Astrazeneca Ab Dérivés de pyridine substitués par 2-amino-6-alkyle utiles comme inhibiteurs de p2y12

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, SOEREN M.: "《Development of a Multi-Kilogram-Scale Synthesis of AZD1283: A Selective and Reversible Antagonist of the P2Y12 Receptor》", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 *
ZHANG, GUANG-LIANG: "《Synthesis and characterization of novel sulfonylurea derivatives》", 《CHEMICAL RESEARCH IN CHINESE UNIVERSITIES》 *

Also Published As

Publication number Publication date
WO2020119590A1 (fr) 2020-06-18

Similar Documents

Publication Publication Date Title
CN111225915B (zh) 作为pad抑制剂的咪唑并吡啶化合物
JP7575952B2 (ja) １５－ｐｇｄｈ阻害薬
TWI330081B (en) New compounds, their preparations and their use in treatment and/or prevention of disease associated with glycogen synthase kinase-3
EP3510025B1 (fr) Inhibiteurs hétéroaryles de pad4
EP3580220A1 (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
CN106459042A (zh) 抗纤维化吡啶酮类
KR20140040774A (ko) 이미다조피리딘 화합물
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
CN104684915A (zh) 新型双环衍生物
CN105008367A (zh) 作为钾离子通道抑制剂的吡咯并三嗪类化合物
TW200813047A (en) Substituted prolinamides, the preparation thereof and the use thereof as medicaments
KR20150105466A (ko) 옥사졸리돈계 화합물 및 이의 제조방법과 용도
EP3704118A1 (fr) Aminoimidazopyridazines en tant qu'inhibiteurs de kinase
HK1223357A1 (zh) 作為離子通道調節劑的稠合雜環化合物
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
CN107787319A (zh) 作为tnf活性的调节剂的吲唑衍生物
RU2606635C2 (ru) Новое соединение, проявляющее ингибиторную активность в отношении parp
KR100588249B1 (ko) 테트라하이드로벤즈인돌 유도체
WO2019189555A1 (fr) Composé hétérocyclique
CA2598861A1 (fr) Composes organiques
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
CN106795152A (zh) 蛋白激酶抑制剂
TW201111367A (en) Hedgehog signal inhibitor
CA2623154A1 (fr) Nouveau derive pyrrole condense
CN111303146A (zh) 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200619